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A B S T R A C T
A new series of some novel pyrazinamide condensed 1,2,3,4-tetrahydropyrimidines was prepared by
reacting of N-(3-oxobutanoyl)pyrazine-2-carboxamide with urea/thiourea and appropriate aldehyde in
the presence of catalytic amount of laboratory made p-toluenesulfonic acid as an efﬁcient catalyst.
Conﬁrmation of the chemical structure of the synthesized compounds (4a–l) was substantiated by TLC,
different spectral data IR, 1H NMR, mass spectra and elemental analysis. The synthesized compounds
were evaluated for acetyl and butyl cholinesterase (AChE and BuChE) inhibitor activity. The titled
compounds exhibited weak, moderate or high AChE and BuChE inhibitor activity. Especially, compound
(4l) showed the best AChE and BuChE inhibitory activity of all the 1,2,3,4-tetrahydropyrimidine
derivatives, with an IC50 value of 0.11mM and 3.4mM.
ã 2014 Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license (http://
creativecommons.org/licenses/by-nc-nd/3.0/).
1. Introduction
Acetylcholine (ACH) acts as an excitatory neurotransmitter for
voluntary muscles in the somatic nervous system and as a
preganglionic and a postganglionic transmitter in the parasympa-
thetic nervous system of vertebrates and invertebrates [1,2]. Acetyl
cholinesterase (AChE) is a terminator enzyme of nerve impulse
transmission at the cholinergic synapses by quick hydrolysis of
ACH to choline and acetate. Inhibition of AChE evolves a strategy
for the treatment of several diseases as Alzheimer’s disease (AD),
senile dementia, ataxia, myasthenia gravis and Parkinson’s disease
[3]. AD is one form of senile dementia, which occurs due to various
neuropathological conditions such as senile plaques and neuroﬁ-
brillary tangles. It is themost common dementias that affect half of
the population aged 85 years [4,5] and seventh main cause of life
lost affecting 5.3 million people over the world. In AD, growing
numbers of nerve cells degenerate and die along with loss in
synapse throughwhich information ﬂows fromand to the brain. As
a result, cognitive impairment and dementia occur [6]. The
neuropathology of AD is generally characterized by the presence of
numerous amyloidal b-peptide (Ab) plaques, neuroﬁbrillary
tangles (NFT), and degeneration or atrophy of the basal forebrain
cholinergic neurons. The loss of basal forebrain cholinergic cells
results in an important reduction in ACh level, which plays an
important role in the cognitive impairment associatedwith AD [7].
Both cholinesterase enzymes acetylcholinesterase (AChE) and
butyrylcholinesterase (BChE) are involved in the hydrolysis of
acetylcholine; however, studies showed that as the disease
progresses, the activity of AChE decreases while the activity of
BChE remains unaffected or even increases [8]. In the brain of
advanced stagedAD patients, BChE can compensate for AChEwhen
the activity of AChE is inhibited by AChE inhibitors. Thus, BChE
hydrolyses the already depleted levels of ACh in these patients.
Furthermore, restoration of ACh levels by BChE inhibition seems to
occur without apparent adverse effects [9,10]. It has been also
proposed that individuals with low-activity of BChE can sustain
cognitive functions better comparing two individuals with normal
BChE activity [11].
Pyrimidine derivatives comprise a diverse and interesting
group of drugs is extremely important for their biological activities.
Dihydropyrimidine and their derivatives have attracted increasing
interest owing to their therapeutic and pharmaceutical properties,
such as antiviral, antitubercular [12,13], antimicrobial agent [14–
18] antagonists of the human adenosine A2A receptor [19],
cyclooxygenase-2 inhibitory activity [20,21], tyrosine kinase
inhibitors, antiamoebic activity [22,23], cytotoxicity [24,25] and
acetyl cholinesterase inhibitor activity [26]. The discovery during
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the 1930s that a dihydropyridine (dihydronicotinamide derivative,
NADH), “hydrogen-transferring coenzyme” consequently became
important in biological system, has generated numerous studies on
the biochemical properties of dihydropyridines and their bio-
isosteres dihydropyrimidines. The search for more suitable
preparation of tetrahydropyrimidinones continues today.
The chemical structure of pyrazinamide provides a most
valuable molecular template for the development of agents able
to interact with a wide variety of biological activities [27].
Tetrahydropyrimidines are structurally similar to dihydropyrimi-
dines. Hence, it was thought worthwhile to synthesize new
congeners by incorporating pyrazinamide with 1,2,3,4-tetrahy-
dropyrimidinonesmoieties in a singlemolecular framework and to
evaluate their acetyl and butyl cholinesterase inhibitor activity.
2. Experimental
2.1. Materials and methods
All chemicals were supplied by E. Merck (Germany) and SD ﬁne
chemicals (India). Melting points were determined by the open
tube capillary method and are uncorrected. The purity of the
compounds was checked on thin layer chromatography (TLC)
plates (silica–gel G) in the solvent system, ethanol, chloroform,
ethyl acetate (6:2:2); the spotswere located under iodine vapors or
UV light. IR spectrum was obtained on a PerkinElmer 1720 FT-IR
spectrometer (KBr Pellet). 1H NMR spectra were recorded or a
Bruker DRX-300 (300MHz FT-NMR) spectrometer using DMSO-d6
as solvent and TMS as internal standard. Mass spectra were
obtained using Shimadzu LCMS 2010A under ESI ionization
technique. Elemental analyses (C, H, and N) were performed on
PerkinElmer model 240C analyzer.
2.2. Preparation of N-(3-oxobutanoyl)pyrazine-2-carboxamide (3)
Pyrazinamide 1 (0.01M) and ethyl acetoacetate 2 (0.01M) were
mixed in presence 10ml of glacial acetic acid and reﬂuxed for
approximately 3.0 h. The colorless liquid formed was then heated
on a water bath to remove the alcohol formed during the reaction.
After allowing the reaction mixture to cool, crude crystals were
obtained. Puriﬁcation was performed by stirring crude crystals
with cold diethyl ether for approximately 20min using a
mechanical stirrer. Allowing it to stand for 15min, followed by
ﬁltration, resulted in the third compound in a pure form of N-(3-
oxobutanoyl)pyrazine-2-carboxamide 3.
2.2.1. General procedure
2.2.1.1. Preparation of 1,2,3,4-tetrahydropyrimidines by microwave
irradiation method (4a–l). The mixture of N-(3-oxobutanoyl)
pyrazine-2-carboxamide (0.005M), urea/thiourea (0.0075M),
and appropriate aldehyde (0.005M) with a catalytic amount of
laboratory made p-toluenesulfonic acid in 10ml of ethanol was
subjected to microwave irradiation (300W) for 12min at the
interval of 10 s. The reactions were monitored through TLC using
the appropriate solvent system. After the reaction was complete,
the reaction mixture was cooled in a refrigerator and ﬁltered. The
precipitate obtainedwaswashed thoroughly with water to remove
unreacted urea/thiourea and dried. The crude solid product was
recrystallized with ethanol to give the pure compounds (4a–l).
2.3. Analytical data
2.3.1. N-(3-Oxobutanoyl)pyrazine-2-carboxamide (3)
Light-red-colored solid, M.P.: 162–164 C; yield: 69%; IR (KBr,
cm1): 3324 (N—H), 2952 (AliC—H), 1728 (C¼O, ketone), 1688
(C¼O, amide), 1592 (C¼C), 1343 (C—N); 1H NMR (DMSO-d6) d: 2.05
(s, 3H, CH3), 2.87 (s, 2H, CH2), 8.78 (s, 1H, Ar—H), 8.93 (s, 1H, Ar—H),
9.08 (s, 1H, Ar—H), 9.43 (s, 1H, NH); calculated for C9H9N3O3: C,
52.17; H, 4.38; N, 20.28; found C, 52.12; H, 4.52; N, 20.33.
2.3.2. 6-Methyl-2-oxo-4-phenyl-N-(pyrazin-2-ylcarbonyl)-1,2,3,4-
tetrahydropyrimidine-5-carboxamide (4a)
Dark-brownish solid, M.P.: 284–286 C; yield: 70%; IR (KBr,
cm1): 3246 (N—H), 3152 (Ar—C—H), 2968 (Ali—C—H), 1674 (C¼O,
amide), 1583 (C¼C), 1248 (O—C); 1H NMR (DMSO-d6) d: 2.09 (s, 3H,
CH3), 5.45 (s, 1H, CH), 7.12–7.23 (m, 5H, Ar—H), 8.78 (s, 1H, Ar—H),
8.93 (s, 1H, Ar—H), 9.08 (s, 1H, Ar—H), 9.41 (s, 1H, NH), 9.76 (s, 1H,
NH), 10.11 (s, 1H, NH); MS (m/z): (M+1) calculated 338.12; found
338.07; calculated for C17H15N5O3: C, 60.53; H, 4.48; N, 20.76;
found C, 60.48; H, 4.53; N, 20.82.
2.3.3. 6-Methyl-4-phenyl-N-(pyrazin-2-ylcarbonyl)-2-thioxo-1,2,3,4-
tetrahydropyrimidine-5-carboxamide (4b)
Ash-colored solid, M.P.: 296–298 C; yield: 77%; IR (KBr, cm1):
3253 (N—H), 3166 (Ar—C—H), 2948 (Ali—C—H),1677 (C¼O, amide),
1584 (C¼C),1888 (C¼S),1192 (O—C); 1HNMR (DMSO-d6) d: 2.06 (s,
3H, CH3), 5.38 (s, 1H, CH), 7.09–7.25 (m, 5H, Ar—H), 8.78 (s, 1H, Ar—
H), 8.93 (s, 1H, Ar—H), 9.08 (s, 1H, Ar—H), 9.39 (s, 1H, NH), 9.82 (s, 1H,
NH), 10.08 (s, 1H, NH); MS (m/z): (M+1) calculated 354.10; found
354.04. Calculated for C17H15N5O2S: C, 57.78; H, 4.28; N, 19.82;
found C, 57.83; H, 4.22; N, 19.87.
2.3.4. 6-Methyl-4-(3-nitrophenyl)-2-oxo-N-(pyrazin-2-ylcarbonyl)-
1,2,3,4-tetrahydropyrimidine-5-carboxamide (4c)
Light-yellowish solid, M.P.: 313–315 C; yield: 76%; IR (KBr,
cm1): 3276 (N—H), 3168 (Ar—C—H), 2984 (Ali—C—H), 1678 (C¼O,
amide), 1558 (C¼C), 1162 (O—C); 1H NMR (DMSO-d6) d: 2.07 (s, 3H,
CH3), 5.49 (s, 1H, CH), 7.39–7.43 (d, 2H, Ar—H), 7.97–8.02 (d, 2H, Ar—
H), 8.78 (s, 1H, Ar—H), 8.93 (s, 1H, Ar—H), 9.08 (s, 1H, Ar—H), 9.24 (s,
1H, NH), 9.68 (s, 1H, NH), 10.06 (s, 1H, NH); MS (m/z): (M+1)
calculated 383.10; found 383.15; calculated for C17H14N6O5: C,
53.40; H, 3.69; N, 21.98; found C, 53.44; H, 3.75; N, 21.94.
2.3.5. 6-Methyl-4-(3-nitrophenyl)-N-(pyrazin-2-ylcarbonyl)-2-
thioxo-1,2,3,4-tetrahydropyrimidine-5-carboxamide (4d)
Light-bluish solid, M.P.: 357–359 C; yield: 71%; IR (KBr, cm1):
3257 (N—H), 3164 (Ar—C—H), 2971 (Ali—C—H),1678 (C¼O, amide),
1562 (C¼C), 1865 (C¼S), 1174 (O—C); 1H NMR (DMSO-d6) d: 2.03 (s,
3H, CH3), 5.39 (s, 1H, CH), 7.42–7.47 (d, 2H, Ar—H), 7.98–8.04 (d, 2H,
Ar—H), 8.78 (s, 1H, Ar—H), 8.93 (s, 1H, Ar—H), 9.08 (s, 1H, Ar—H), 9.17
(s, 1H, NH), 9.61 (s, 1H, NH), 10.04 (s, 1H, NH); MS (m/z): (M+1)
calculated 399.08; found 400.03; calculated for C17H14N6O4S: C,
51.25; H, 3.54; N, 21.09; found C, 51.30; H, 3.59; N, 21.15.
2.3.6. 4-(3-Chlorophenyl)-6-methyl-2-oxo-N-(pyrazin-2-
ylcarbonyl)-1,2,3,4-tetrahydropyrimidine-5-carboxamide (4e)
Light-greenish solid, M.P.: 357–359 C; yield: 79%; IR (KBr,
cm1): 3276 (N—H), 3134 (Ar—C—H), 2948 (Ali—C—H), 1672 (C¼O,
amide), 1569 (C¼C), 1189 (O—C); 1H NMR (DMSO-d6) d: 2.09 (s, 3H,
CH3), 5.51 (s, 1H, CH), 6.98–7.13 (m, 4H, Ar—H), 8.78 (s, 1H, Ar—H),
8.93 (s, 1H, Ar—H), 9.08 (s, 1H, Ar—H), 9.14 (s, 1H, NH), 9.49 (s, 1H,
NH), 10.05 (s, 1H, NH); MS (m/z): (M+1) calculated 372.08; found
372.02; calculated for C17H14ClN5O3: C, 54.92; H, 3.80; N, 18.84;
found C, 54.97; H, 3.74; N, 18.90.
2.3.7. 4-(3-Chlorophenyl)-6-methyl-N-(pyrazin-2-ylcarbonyl)-2-
thioxo-1,2,3,4-tetrahydropyrimidine-5-carboxamide (4f)
Ash-colored solid, M.P.: 324–326 C; yield: 80%; IR (KBr, cm1):
3254 (N—H), 3163 (Ar—C—H), 2978 (Ali—C—H),1681 (C¼O, amide),
1548 (C¼C),1879 (C¼S),1146 (O—C); 1H NMR (DMSO-d6) d: 2.07 (s,
3H, CH3), 5.44 (s, 1H, CH), 7.06–7.24 (m, 4H, Ar—H), 8.78 (s, 1H,
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Ar—H), 8.93 (s, 1H, Ar—H), 9.08 (s, 1H, Ar—H), 9.25 (s, 1H, NH), 9.48
(s, 1H, NH), 10.12 (s, 1H, NH); MS (m/z): (M+1) calculated 388.06;
found 388.11; calculated for C17H14ClN5O2S: C, 52.65; H, 3.64; N,
18.06; found C, 52.71; H, 3.69; N, 18.12.
2.3.8. 4-(4-Fluorophenyl)-6-methyl-2-oxo-N-(pyrazin-2-ylcarbonyl)-
1,2,3,4-tetrahydropyrimidine-5-carboxamide (4g)
Light-bluish solid, M.P.: 356–358 C; yield: 81%; IR (KBr, cm1):
3274 (N—H), 3186 (Ar—C—H), 2951 (Ali—C—H), 1678 (C¼O, amide),
1547 (C¼C), 1175 (O-C); 1H NMR (DMSO-d6) d: 2.05 (s, 3H, CH3),
5.52 (s, 1H, CH), 6.95 (d, 2H, Ar—H), 7.15 (d, 2H, Ar—H), 8.78 (s, 1H,
Ar—H), 8.93 (s, 1H, Ar—H), 9.08 (s, 1H, Ar—H), 9.17 (s, 1H, NH), 9.51 (s,
1H, NH), 10.02 (s, 1H, NH); MS (m/z): (M+1) calculated 356.11;
found 356.17; calculated for C17H14FN5O3: C, 57.46; H, 3.97; N,
19.71; found C, 57.51; H, 4.03; N, 19.76.
2.3.9. 4-(4-Fluorophenyl)-6-methyl-N-(pyrazin-2-ylcarbonyl)-2-
thioxo-1,2,3,4-tetrahydropyrimidine-5-carboxamide (4h)
Light-yellowish solid, M.P.: 367–369 C; yield 83%; IR (KBr,
cm1): 3242 (N—H), 3181(Ar—C—H), 2948 (Ali—C—H), 1678 (C¼O,
amide),1564 (C¼C),1858 (C¼S),1148 (O—C); 1HNMR (DMSO-d6) d:
2.03 (s, 3H, CH3), 5.48 (s, 1H, CH), 6.98 (d, 2H, Ar—H), 7.21 (d, 2H, Ar—
H), 8.78 (s, 1H, Ar—H), 8.93 (s, 1H, Ar—H), 9.08 (s, 1H, Ar—H), 9.28 (s,
1H, NH), 9.59 (s, 1H, NH), 10.04 (s, 1H, NH); MS (m/z): (M+1)
calculated 372.09; found 372.15; calculated for C17H14FN5O2S: C,
54.98; H, 3.80; N, 18.86; found C, 55.03; H, 3.86; N, 18.92.
2.3.10. 4-(4-Chlorophenyl)-6-methyl-2-oxo-N-(pyrazin-2-
ylcarbonyl)-1,2,3,4-tetrahydropyrimidine-5-carboxamide (4i)
Ash-colored solid, M.P.: 341–343 C; yield 79%; IR (KBr, cm1):
3256 (N—H), 3162 (Ar—C—H), 2974 (Ali—C—H),1681 (C¼O, amide),
1548 (C¼C),1883 (C¼S),1168 (O—C); 1HNMR (DMSO-d6) d: 2.07 (s,
3H, CH3), 5.45 (s, 1H, CH), 7.05 (d, 2H, Ar—H), 7.23 (d, 2H, Ar—H), 8.78
(s, 1H, Ar—H), 8.93 (s, 1H, Ar—H), 9.08 (s, 1H, Ar—H), 9.09 (s, 1H, NH),
9.54 (s, 1H, NH), 10.12 (s, 1H, NH); MS (m/z): (M+1) calculated
372.08; found 372.13; calculated for C17H14ClN5O3: C, 54.92; H,
3.80; N, 18.84; found C, 54.97; H, 3.84; N, 18.90.
2.3.11. 4-(4-Chlorophenyl)-6-methyl-N-(pyrazin-2-ylcarbonyl)-2-
thioxo-1,2,3,4-tetrahydropyrimidine-5-carboxamide (4j)
Light-bluish solid, M.P.: 331–333 C; yield 74%; IR (KBr, cm1):
3238 (N—H), 3164 (Ar—C—H), 2937 (Ali—C—H),1676 (C¼O, amide),
1574 (C¼C),1889 (C¼S),1194 (O—C); 1H NMR (DMSO-d6) d: 2.08 (s,
3H, CH3), 5.44 (s, 1H, CH), 7.08 (d, 2H, Ar—H), 7.23 (d, 2H, Ar—H), 8.78
(s, 1H, Ar—H), 8.93 (s, 1H, Ar—H), 9.08 (s, 1H, Ar—H), 9.21 (s, 1H, NH),
9.59 (s, 1H, NH), 10.11 (s, 1H, NH); MS (m/z): (M+1) calculated
388.06; found 388.00; calculated for C17H14ClN5O2S: C, 52.65; H,
3.64; N, 18.06; found C, 52.59; H, 3.69; N, 18.12.
2.3.12. 6-Methyl-2-oxo-N-(pyrazin-2-ylcarbonyl)-4-(pyridin-4-yl)-
1,2,3,4-tetrahydropyrimidine-5-carboxamide (4k)
Light-yellowish solid, M.P.: 295–297 C; yield 77%; IR (KBr,
cm1): 3228 (N—H), 3172 (Ar—C—H), 2957 (Ali—C—H), 1684 (C¼O,
amide),1581 (C¼C),1848 (C¼S),1175 (O—C); 1HNMR (DMSO-d6) d:
2.01 (s, 3H, CH3), 5.43 (s, 1H, CH), 7.45 (d, 2H, Ar—H), 8.34 (d, 2H, Ar—
H), 8.78 (s, 1H, Ar—H), 8.93 (s, 1H, Ar—H), 9.08 (s, 1H, Ar—H), 9.16 (s,
1H, NH), 9.51 (s, 1H, NH), 10.01 (s, 1H, NH); MS (m/z): (M+1)
calculated 339.12; found 339.18; calculated for C16H14N6O3: C,
56.80; H, 4.17; N, 24.84; found C, 56.85; H, 4.12; N, 24.90.
2.3.13. 6-Methyl-N-(pyrazin-2-ylcarbonyl) -4-(pyridin-4-yl) -2-
thioxo-1,2,3,4-tetrahydropyrimidine-5-carboxamide (4l)
Ash-colored solid, M.P.: 317–319 C; yield 73%; IR (KBr, cm1):
3258 (N—H), 3192 (Ar—C—H), 2936 (Ali—C—H),1677 (C¼O, amide),
1583 (C¼C),1891 (C¼S),1138 (O—C); 1H NMR (DMSO-d6) d: 2.05 (s,
3H, CH3), 5.49 (s, 1H, CH), 7.36 (d, 2H, Ar—H), 8.54 (d, 2H, Ar—H), 8.78
(s, 1H, Ar—H), 8.93 (s, 1H, Ar—H), 9.08 (s, 1H, Ar—H), 9.32 (s, 1H, NH),
9.76 (s, 1H, NH), 10.18 (s, 1H, NH); MS (m/z): (M+1) calculated
355.09; found 355.14; calculated for C16H14N6O2S: C, 54.23; H,
3.98; N, 23.71; found C, 54.29; H, 3.95; N, 23.77.
2.4. Acetylcholinesterase inhibitory activity
2.4.1. In vitro inhibition studies on AChE and BuChE
Acetylcholinesterase (AChE, from electric eel), butyl cholines-
terase (BuChE, from equine serum), 5,50-dithiobis-(2-nitrobenzoic
acid) (Ellman’s reagent, DTNB), acetylthiocholine chloride (ATC),
butylthiocholine chloride (BTC), and hydrochloride were pur-
chased from Sigma–Aldrich. The 1,2,3,4-tetrahydropyrimidines
derivatives were dissolved in DMSO and diluted in 0.1M KH2PO4/
K2HPO4 buffer (pH 8.0) to provide a ﬁnal concentration range.
DMSO was diluted to a concentration in excess of 1 in 10,000, and
no inhibitory action on either AChE or BuChE was detected in
separate prior experiments.
2.4.2. In vitro AChE assay
All the assays were carried out under 0.1M KH2PO4/K2HPO4
buffers, pH 8.0, using a Shimadzu UV-2450 spectrophotometer.
Enzyme solutions were prepared to give 2.0units/ml in 2ml
aliquots. The assay medium (1ml) consisted of phosphate buffer
(pH 8.0), 50ml of 0.01MDTNB,10ml of enzyme, and 50ml of 0.01M
substrate (ACh chloride solution). Test compounds were added to
the assay solution and preincubated at 37 C with the enzyme for
15min followed by the addition of substrate. The activity was
determined by measuring the increase in absorbance at 412nm at
1min intervals at 37 C. Calculations were performed according to
the method of the equation in Ellman’s method [28]. Each
concentration was assayed in triplicate. In vitro BuChE assay was
similar to the method used for AChE.
3. Results and discussion
A series of 12 novel pyrazinamide condensed 1,2,3,4-tetrahy-
dropyrimidines of biological interest were synthesized and
evaluated for acetyl and butyl cholinesterase inhibitor activity,
all the compounds were characterized by IR, 1H NMR, MS and
elemental analysis of their structures.
3.1. Chemistry
Synthesis of 1,4-dihydropyrimidines by adopting the Biginelli
synthetic protocol [29] involving one potmulticomponent reaction
was performed by following steps as outlined in Fig. 1. In the ﬁrst
step, ethyl acetoacetate 2 and pyrazinamide 1 in presence 10ml of
glacial acetic acid reacted under neat conditions resulting in the
formation of N-(3-oxobutanoyl)pyrazine-2-carboxamide 3 with
the yield of 74%. The N-(3-oxobutanoyl)pyrazine-2-carboxamide
was further taken for the Biginelli condensation reaction by
reacting it with urea/thiourea and appropriate aldehyde in the
presence of catalytic amount of laboratory made p-toluenesul-
phonic acid [30]. The advantages of the catalyst were better yields
and do not require dry solvents. The ﬁrst step in the mechanism of
the Biginelli reaction is the acid-catalyzed condensation of the urea
with the aldehyde. This reaction begins with protonation of the
aldehyde by the acid and is followed by an attack of the amine from
urea. Proton transfer steps, then result in a protonated alcohol
which leaves as water to form an N-acyliminium ion intermediate
[31], subsequently enol form of the b-keto ester attacks the N-
acyliminium ion to generate an open chain ureide which readily
cyclizes to a tetrahydropyrimidines. The reaction timeswere found
to be 12min. The IR spectra of compounds (4a–l) showed strong
absorption bands for the amine group (3233–3373 cm1), amide
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group (1672–1684 cm1), aliphatic C—H stretching (2926–
2994 cm1), aromatic C—H stretching (3134–3212 cm1) and
aromatic C¼C stretching (1539–1591 cm1). 1H NMR spectrum
of compounds 4a–l showed a methyl group protons singlet at
(2.01–2.09ppm), CH-R protons singlet at (5.34–5.52ppm), aro-
matic protons triplet at (6.84–7.30ppm) and amine protons singlet
at (9.07–10.18ppm). The mass spectra and elemental analysis
results were within 0.6% of the theoretical values. Totally, twelve
compounds (4a–l) various substituted 1,2,3,4-tetrahydropyrimi-
dines, were synthesized with the yield ranging from 70% to 83%.
These conditions enable this method to be applicable for the
synthesis of 1,2,3,4-tetrahydropyrimidines based heterocyclic
compounds. The present protocol best describes the synthesis of
1,2,3,4-tetrahydropyrimidines. All the reported 1,2,3,4-tetrahydro-
pyrimidines compounds were found to be novel and not reported
elsewhere.
3.2. Acetylcholinesterase inhibitory activity
Among the novel substituted 1,2,3,4-tetrahydropyrimidine
derivatives for treating AD, their anti-cholinesterase activities
(compounds 4a–l) was assayed according to Ellman’s method on
acetyl cholinesterase (AChE) from electric eel using commercial
donepezil HCl as the reference standard [32,33]. The butyls
cholinesterase’s (BuChE) inhibitory on equine serum BuChE were
also examined by the samemethod. Inhibition of AChE activities of
the synthesized compounds is shown in Fig. 2 and Table 1. The data
listed in Fig. 2 and Table 1 clearly shows that most of the designed
compounds exhibited good to moderate inhibitory activities
toward the AChE and BuChE inhibition are summarized in Fig. 2
and Table 1. All the synthesized 1,2,3,4-tetrahydropyrimidine
derivatives were potent inhibitors of AChE, with IC50 values
ranging from micro molar to sub-micro molar. Especially,
compound 4l showed the best AChE and BuChE inhibitory activity
of all the 1,2,3,4-tetrahydropyrimidine derivatives, with an IC50
value of 0.11mM and 3.4mM. Among the compounds reported
herein, compound 4l is arguably the most potent.
4. Structural activity relationship
Analyzing the activities of the synthesized compounds, the
following structure activity relationships (SAR)were obtained. The
ﬁfth position of 1,2,3,4-tetrahydropyrimidines contain N-(3-
oxobutanoyl)pyrazine-2-carboxamide group contributed toward
acetyl and butyl cholinesterase inhibitor activity, and fourth
positions of 1,2,3,4-tetrahydropyrimidines contain substituted
phenyl and hetero aromatic ring responsible acetyl and butyl
cholinesterase inhibitor activity [26]. Heteroaryl substituted
compounds at 4th position it enhance the potency of the
compounds when compare with the unsubstituted or substituted
aryl containing compounds. Substituted atom or group of atom
must be the strong electron withdrawing nature of potent activity
because it decreases electron density in the ring due to inductive
effect. Fluoride and chloride substitution at fourth position of
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Fig. 1. Synthesis of compounds (4a–l). Reagents and conditions: (a) reﬂux 3.0 h, CH3COOH; (b) C2H5OH, p-toluenesulphonic acid, and microwave irradiation (300W) for
12min.
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phenyl ring showed potent action because of strong electron
withdrawing nature due to inductive effect. Substitution of ﬂuro,
chloro group at third and fourth position of phenyl ring showed
potent actionwhen compare with nitro atom. The second position
sulfur substituted derivatives most potent when compare with
oxygen atoms. Among the compounds reported herein, compound
4l is arguably the most potent when compared with current
therapeutic agent donepezil HCl because heteroaryl ring present at
4th position of 1,2,3,4-tetrahydropyrimidines it enhances the
acetyl and butyl cholinesterase inhibitor activity (Fig. 2 and
Table 1).
5. Conclusion
In summary, a series of novel 1,2,3,4-tetrahydropyrimidines of
biological interest were synthesized and analyzed for their
structures. The libraries of compounds were prepared by using
laboratory made p-toluenesulfonic acid as an efﬁcient catalyst
when comparewith Lewis acid. The importance of substitutions at
the fourth positions of 1,2,3,4-tetrahydropyrimidines was studied
toward the acetyl and butyl cholinesterase inhibitor activity. The
acetyl and butyl cholinesterase inhibitor activity data revealed that
the all synthesized compounds proved to be active against acetyl
and butyl cholinesterase enzymes. Almost all of the titled
compounds exhibited weak, moderate, or high acetyl and butyl
cholinesterase inhibitor activity. Compound 4l showed potent
acetyl and butyl cholinesterase inhibitor activity when compare
with the donepezil HCl, our present study makes it an interesting
compound when compared to the current therapeutic agents and
are considered the candidates to investigate further for the
same.
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Table 1
Synthesized 1,2,3,4-tetrahydropyrimidines: in vitro acetyl and butyl cholinesterase inhibitor activity
[TD$INLINE]
NH
N
H
CH3 X
RO
NH
O
N
N
.
Serial no. Compound R X AChE
IC50 (mM) SEM
BuChE
IC50 (mM) SEM
1 4a Phenyl O 5.350.01 7.210.01
2 4b Phenyl S 5.260.01 6.750.01
3 4c 3-Nitorophenyl O 2.540.01 5.930.01
4 4d 3-Nitorophenyl S 1.820.01 5.380.01
5 4e 3-Chlorophenyl O 1.210.01 4.960.01
6 4f 3-Chlorophenyl S 1.050.01 4.310.01
7 4g 4-Flurophenyl O 0.860.01 4.840.01
8 4h 4-Flurophenyl S 0.750.01 3.930.01
9 4i 4-Chlorophenyl O 0.940.01 4.750.01
10 4j 4-Chlorophenyl S 0.880.01 4.130.01
11 4k 4-Pyridyl O 0.190.01 3.920.01
12 4l 4-Pyridyl S 0.110.01 3.460.01
13 Donepezil HCl Standard – 0.130.01 3.580.01
[(Fig._2)TD$FIG]
Fig. 2. In vitro acetyl and butyl cholinesterase inhibitor activity of compounds (4a–l) and Donepezil HCl (std.).
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Appendix A. Supplementary data
Supplementary data associatedwith this article can be found, in
the online version, at http://dx.doi.org/10.1016/j.btre.2014.10.007.
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